Biogen (Brazil) Performance
| BIIB34 Stock | BRL 150.16 2.24 1.47% |
The firm shows a Beta (market volatility) of 0.0769, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Biogen's returns are expected to increase less than the market. However, during the bear market, the loss of holding Biogen is expected to be smaller as well. At this point, Biogen Inc has a negative expected return of -0.25%. Please make sure to confirm Biogen's information ratio, total risk alpha, potential upside, as well as the relationship between the jensen alpha and treynor ratio , to decide if Biogen Inc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Biogen Inc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's forward indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 1.3 B | |
| Total Cashflows From Investing Activities | -563.7 M |
Biogen |
Biogen Relative Risk vs. Return Landscape
If you would invest 17,694 in Biogen Inc on September 24, 2024 and sell it today you would lose (2,678) from holding Biogen Inc or give up 15.14% of portfolio value over 90 days. Biogen Inc is generating negative expected returns and assumes 1.5549% volatility on return distribution over the 90 days horizon. Simply put, 13% of stocks are less volatile than Biogen, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Biogen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biogen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biogen Inc, and traders can use it to determine the average amount a Biogen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1595
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BIIB34 |
Estimated Market Risk
| 1.55 actual daily | 13 87% of assets are more volatile |
Expected Return
| -0.25 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Biogen is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biogen by adding Biogen to a well-diversified portfolio.
Biogen Fundamentals Growth
Biogen Stock prices reflect investors' perceptions of the future prospects and financial health of Biogen, and Biogen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biogen Stock performance.
| Return On Equity | 0.2 | |||
| Return On Asset | 0.076 | |||
| Profit Margin | 0.28 % | |||
| Operating Margin | 0.29 % | |||
| Current Valuation | 230.79 B | |||
| Shares Outstanding | 867.48 M | |||
| Price To Earning | 6.38 X | |||
| Price To Book | 3.28 X | |||
| Price To Sales | 21.53 X | |||
| Revenue | 10.98 B | |||
| EBITDA | 2.88 B | |||
| Cash And Equivalents | 3.91 B | |||
| Cash Per Share | 20.16 X | |||
| Total Debt | 6.27 B | |||
| Debt To Equity | 46.10 % | |||
| Book Value Per Share | 14.82 X | |||
| Cash Flow From Operations | 3.64 B | |||
| Earnings Per Share | 16.90 X | |||
| Total Asset | 23.88 B | |||
About Biogen Performance
By analyzing Biogen's fundamental ratios, stakeholders can gain valuable insights into Biogen's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biogen has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biogen has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen operates under Drug Manufacturers - Major classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 7800 people.Things to note about Biogen Inc performance evaluation
Checking the ongoing alerts about Biogen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biogen Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biogen Inc generated a negative expected return over the last 90 days |
- Analyzing Biogen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biogen's stock is overvalued or undervalued compared to its peers.
- Examining Biogen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biogen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biogen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biogen's stock. These opinions can provide insight into Biogen's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Biogen Stock analysis
When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |